<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="251">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213199</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.29088</org_study_id>
    <nct_id>NCT01213199</nct_id>
  </id_info>
  <brief_title>Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars</brief_title>
  <official_title>Efficacy and Safety of Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars. A Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the
      treatment of atrophic acne scars.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Global Scarring Severity</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Grade Level:
Macular disease
Mild disease
Moderate disease
Severe disease</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acne Scars</condition>
  <arm_group>
    <arm_group_label>Differin 0.3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DifferinÂ® 0.3% Gel
Adapalene 0.3%
Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene</intervention_name>
    <description>Adapalene Gel 0.3%</description>
    <arm_group_label>Differin 0.3%</arm_group_label>
    <other_name>Differin 0.3%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects of any race, aged 18 to 50 years inclusive

          -  Subjects with a past history of acne and with moderate to severe facial atrophic acne
             scars

        Exclusion Criteria:

          -  Subjects with active inflammatory acne lesions

          -  Subjects with hypertrophic acne scars
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manisha J. Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Institut</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manisha PATEL</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://galderma.com/</url>
  </link>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 9, 2015</lastchanged_date>
  <firstreceived_date>September 30, 2010</firstreceived_date>
  <firstreceived_results_date>November 22, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
